Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-10

Study Completion Date

2027-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Efficacy of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder

NCT05529225

Opioid Use Disorder

COMPLETED

Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

NCT05339256

Opioid Use Disorder

NOT_YET_RECRUITING PHASE2

Improving Office Based Treatment of Opioid Use Disorder With Technology

NCT03586466

Opioid-use Disorder

UNKNOWN NA

Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution

NCT04059016

Opioid Abuse and Addiction

COMPLETED

Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention

NCT06341608

Opioid Use Disorder

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Receiving Intervention

Group Type EXPERIMENTAL

Telemedicine Buprenorphine Treatment

Intervention Type DRUG

With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telemedicine Buprenorphine Treatment

With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of Opioid Use Disorder (OUD)
* Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication
* Speak and understand English

Exclusion Criteria

* History of allergic reaction to buprenorphine
* Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care)
* Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No